Evidence map›Paper›PMID 41893557›Full record

ArticleToxins2026

RTP004 Peptide Binds to Botulinum Neurotoxin, Increases Cell Surface Binding, and Enhances Cellular SNAP-25 Cleavage.

Andre F Batista, Ratnesh Singh, Frank Lee, Shaoqiu Zhuo, Dmitri Leonoudakis, Conor J Gallagher

Abstract read
In one paragraph

Article in Toxins, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Andre F BatistaRevance, 1222 Demonbreun St Suite 2000, Nashville, TN 37203, USA.
Ratnesh SinghRevance, 1222 Demonbreun St Suite 2000, Nashville, TN 37203, USA.
Frank LeeRevance, 1222 Demonbreun St Suite 2000, Nashville, TN 37203, USA.
Shaoqiu ZhuoRevance, 1222 Demonbreun St Suite 2000, Nashville, TN 37203, USA.
Dmitri LeonoudakisRevance, 1222 Demonbreun St Suite 2000, Nashville, TN 37203, USA.
Conor J GallagherRevance, 1222 Demonbreun St Suite 2000, Nashville, TN 37203, USA.ORCID 0000-0002-5488-6594

Funding

Revance Therapeutics Not applicable
6 · The paper itself

Abstract

DaxibotulinumtoxinA for injection (DAXI) is a botulinum neurotoxin (BoNT) drug product comprising the 150 kDa pure BoNT/A1 as the drug substance formulated with a proprietary stabilizing excipient, RTP004. We hypothesized that RTP004 facilitates localization of BoNT/A1 to the neuronal membrane, resulting in increased BoNT internalization and cleavage of the synaptosomal-associated protein of 25 kDa (SNAP-25) within synaptic terminals. We characterized the interaction between RTP004 and BoNT/A1 using in silico and in vitro techniques. In vitro analyses revealed that negative charges on the BoNT/A1 surface were located on the light chain (LC, the catalytic domain) and the C-terminus of the heavy chain (H

Indexed as

Botulinum Toxins, Type APeptidesSynaptosomal-Associated Protein 25AnimalsCell MembraneHumansProtein BindingBotulinum Toxins, Type APeptidesSnap25 protein, ratSynaptosomal-Associated Protein 25botulinum neurotoxin type AdaxibotulinumtoxinAneuromodulatorpeptidesprotein transduction domainRTP004SNAP-25

Identifiers

PMID41893557
PMCPMC13030680

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.